Medical Research Law & Policy Report® Index-Summary

FABRAZYME

– Fabry disease drug shortage, 551; NIH “march-in” rights, 783

FALSE CLAIMS

– Catholic Healthcare West, qui tam suit untimely (9th Cir.), 115; (U.S., rev den), 662
– St. Jude qui tam suit (D. Mass.), 526; federal intervention sought, 581
– Training grant (S.D.N.Y.), 526

FDA

See FOOD AND DRUG ADMINISTRATION (FDA)

FINANCIAL INDUSTRY STABILIZATION

– Medical research and stimulus funding, report, 139

FLORIDA

– Grant applications, 83; proposed rule, 148
– IRB rules, 26
– Jackson Labs, funding for research facility, 286

FOOD AND DRUG ADMINISTRATION (FDA)

– Advancing regulatory science, 654
– Appointments, science advisor, 24
– Conflicts of interest, CRS report, 177
– Criminal investigations unit, response to GAO report, 182
– FY2011 budget, 411; Senate panel approves, 455
– Grassley questions travel costs, 150
– Interagency chemical assessment program, 488
– Management planning, GAO report, 221
– Regulatory science advancement, 212
– Transparency

– – Advisory panels, 279
– – Proposal issued, 344

FRAUD AND ABUSE

– Alzheimer's study whistleblower suit (D. Mass.), 662; no evidence for falsity, 730
– Authorship credit dispute (E.D. Pa.), 340
– Bone cement trials (E.D. Pa.), 794
– Conflicts of interest

See CONFLICTS OF INTEREST

– False claims, Catholic Healthcare West, qui tam suit (9th Cir.), 115; (U.S., rev den), 662
– Imaging device approvals, whistleblowers, 631
– Kickbacks

– – Boston Scientific resolution, 28
– – Physician group settles (S.D. Ohio), 415

– Misconduct in research

– – Anesthesiologist, pain drug data fabrication admission (D. Mass.), 56; guilty plea, 150; sentenced, 415
– – Australian panel, 255
– – Autism link to vaccines, U.K. MDs guilty, 85; Lancet retraction, 116; MDs struck from register, 350
– – Bogus papers in scientific journals, 756
– – Cancer, plagiarism and falsifying research, no federal jurisdiction (E.D. Pa.), 29
– – Changed FDA procedures, IRB role, Special Report, 155
– – Cost of probes, 567
– – Data falsification, proposed rule, 138
– – Debarment by HHS, no injunction (D.D.C.), 383
– – Defamation claim by medical student against Univ. of Miami (S.D. Fla.), 107
– – Duke researcher suspension, 493; resignation, 763
– – Harvard biologist, 565
– – Integrity studies, HHS grants, 145
– – Paxil clinical trial records (E.D. La.), 589
– – Retraction sought by Mayo Clinic, 384
– – Univ. of Medicine & Dentistry grant application (D.N.J.), 696

– NIH grant fraud allegations (S.D.N.Y.), 27; reconsideration denied, 350; verdict challenged, 793